JP2022513094A5 - - Google Patents

Info

Publication number
JP2022513094A5
JP2022513094A5 JP2021527892A JP2021527892A JP2022513094A5 JP 2022513094 A5 JP2022513094 A5 JP 2022513094A5 JP 2021527892 A JP2021527892 A JP 2021527892A JP 2021527892 A JP2021527892 A JP 2021527892A JP 2022513094 A5 JP2022513094 A5 JP 2022513094A5
Authority
JP
Japan
Prior art keywords
antibody
weeks
psoriasis
patient
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021527892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513094A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059939 external-priority patent/WO2020104943A2/en
Publication of JP2022513094A publication Critical patent/JP2022513094A/ja
Publication of JP2022513094A5 publication Critical patent/JP2022513094A5/ja
Priority to JP2024203887A priority Critical patent/JP2025041599A/ja
Pending legal-status Critical Current

Links

JP2021527892A 2018-11-20 2019-11-19 抗il-23特異的抗体で乾癬を治療する安全かつ有効な方法 Pending JP2022513094A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024203887A JP2025041599A (ja) 2018-11-20 2024-11-22 抗il-23特異的抗体で乾癬を治療する安全かつ有効な方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862769889P 2018-11-20 2018-11-20
US62/769,889 2018-11-20
US201962796673P 2019-01-25 2019-01-25
US62/796,673 2019-01-25
US201962810617P 2019-02-26 2019-02-26
US62/810,617 2019-02-26
US201962817711P 2019-03-13 2019-03-13
US62/817,711 2019-03-13
US201962915115P 2019-10-15 2019-10-15
US62/915,115 2019-10-15
PCT/IB2019/059939 WO2020104943A2 (en) 2018-11-20 2019-11-19 Safe and effective method of treating psoriasis with anti-il-23 specific antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024203887A Division JP2025041599A (ja) 2018-11-20 2024-11-22 抗il-23特異的抗体で乾癬を治療する安全かつ有効な方法

Publications (2)

Publication Number Publication Date
JP2022513094A JP2022513094A (ja) 2022-02-07
JP2022513094A5 true JP2022513094A5 (cg-RX-API-DMAC7.html) 2024-05-09

Family

ID=70727469

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021527892A Pending JP2022513094A (ja) 2018-11-20 2019-11-19 抗il-23特異的抗体で乾癬を治療する安全かつ有効な方法
JP2024203887A Pending JP2025041599A (ja) 2018-11-20 2024-11-22 抗il-23特異的抗体で乾癬を治療する安全かつ有効な方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024203887A Pending JP2025041599A (ja) 2018-11-20 2024-11-22 抗il-23特異的抗体で乾癬を治療する安全かつ有効な方法

Country Status (12)

Country Link
US (2) US11548941B2 (cg-RX-API-DMAC7.html)
EP (1) EP3883607B1 (cg-RX-API-DMAC7.html)
JP (2) JP2022513094A (cg-RX-API-DMAC7.html)
KR (1) KR20210093973A (cg-RX-API-DMAC7.html)
CN (1) CN113395979A (cg-RX-API-DMAC7.html)
AU (1) AU2019383017B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021009287A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120237A1 (cg-RX-API-DMAC7.html)
IL (1) IL283192B2 (cg-RX-API-DMAC7.html)
MA (1) MA55149A (cg-RX-API-DMAC7.html)
MX (1) MX2021005905A (cg-RX-API-DMAC7.html)
WO (1) WO2020104943A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55149A (fr) * 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
EP4305062A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
BR112023018353A2 (pt) * 2021-03-12 2024-02-06 Janssen Biotech Inc Método seguro e eficaz para tratamento da artrite psoriática com anticorpo específico anti-il23
US20240400670A1 (en) * 2021-09-30 2024-12-05 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-il23 antibody fusion protein and uses thereof
JP2025500882A (ja) * 2021-12-17 2025-01-15 ヤンセン バイオテツク,インコーポレーテツド 全身性硬化症の治療のためのil-23特異的抗体
JP2025512860A (ja) * 2022-03-30 2025-04-22 ヤンセン バイオテツク,インコーポレーテツド Il-23に特異的な抗体によって軽度から中等度の乾癬を治療する方法
WO2025202942A1 (en) * 2024-03-29 2025-10-02 Janssen Biotech, Inc. Methods for predicting treatment response in psoriasis

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3587814T2 (de) 1985-03-30 1994-11-10 Marc Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
JP2511932B2 (ja) 1987-02-27 1996-07-03 株式会社日立製作所 内燃機関のトルク制御装置
WO1988006630A1 (en) 1987-03-02 1988-09-07 Genex Corporation Method for the preparation of binding molecules
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US4939666A (en) 1987-09-02 1990-07-03 Genex Corporation Incremental macromolecule construction methods
WO1989006283A1 (en) 1988-01-11 1989-07-13 Ingene (International Genetic Engineering, Inc.) Novel plasmid vector with pectate lyase signal sequence
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US4987893A (en) 1988-10-12 1991-01-29 Rochal Industries, Inc. Conformable bandage and coating material
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
GB8826530D0 (en) 1988-11-12 1988-12-14 Ped Capacitors Ltd Electrical capacitors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
DE3909708A1 (de) 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh Verfahren zur herstellung bispezifischer antikoerper
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
TW212184B (cg-RX-API-DMAC7.html) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2109945T3 (es) 1990-06-01 1998-02-01 Chiron Corp Composiciones y procedimientos para identificar moleculas biologicamente activas.
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
EP0544809B1 (en) 1990-08-24 1998-12-16 Ixsys, Inc. Methods of synthesizing oligonucleotides with random codons
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
IE914504A1 (en) 1990-12-20 1992-07-01 Ixsys Optimization of binding proteins
IE920562A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE4207475A1 (de) 1992-03-10 1993-09-16 Goldwell Ag Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994008038A1 (en) 1992-10-02 1994-04-14 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
JP2901115B2 (ja) 1992-11-13 1999-06-07 三田工業株式会社 定着装置
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
AU6132994A (en) 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5770428A (en) 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
DE4337197C1 (de) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
SE9304060D0 (sv) 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JPH09510201A (ja) 1994-03-07 1997-10-14 メダレツクス・インコーポレーテツド 臨床的効用を有する二重特異性分子
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
JP3659261B2 (ja) 1994-10-20 2005-06-15 モルフォシス・アクチェンゲゼルシャフト 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
US5549551A (en) 1994-12-22 1996-08-27 Advanced Cardiovascular Systems, Inc. Adjustable length balloon catheter
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6331431B1 (en) 1995-11-28 2001-12-18 Ixsys, Inc. Vacuum device and method for isolating periplasmic fraction from cells
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
DE19624387C2 (de) 1996-06-19 1999-08-19 Hatz Motoren Kaltstartvorrichtung
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
DK0826695T3 (da) 1996-09-03 2002-04-15 Gsf Forschungszentrum Umwelt Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US5859246A (en) 1997-01-30 1999-01-12 Neurogen Corporation 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
AU8691398A (en) 1997-08-04 1999-02-22 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
ATE248583T1 (de) 1997-09-29 2003-09-15 Nektar Therapeutics In dosierinhalatoren verwendbare, stabilisierte zubereitungen
AU2661199A (en) 1998-02-06 1999-08-23 Schering Corporation Mammalian receptor proteins; related reagents and methods
ATE474849T1 (de) 1998-04-14 2010-08-15 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP1112286A1 (en) 1998-08-14 2001-07-04 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
DE60041393D1 (de) 1999-03-11 2009-03-05 Schering Corp Cytokine aus säugetieren, verwandte reagenzien und verfahren
US6800460B1 (en) 1999-03-11 2004-10-05 Schering Corporation Mammalian cytokine complexes
JP2002543840A (ja) 1999-05-19 2002-12-24 インサイト・ゲノミックス・インコーポレイテッド 細胞外シグナル伝達分子
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
DE60038304T3 (de) 1999-09-09 2017-04-06 Merck Sharp & Dohme Corp. Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US20020042386A1 (en) 2000-01-31 2002-04-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US6756481B2 (en) 2000-05-10 2004-06-29 Schering Corporation IL-23 receptor binding compositions
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
EP1383800A4 (en) 2001-04-02 2004-09-22 Idec Pharma Corp RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII
SE520605C2 (sv) 2001-06-29 2003-07-29 Flir Systems Ab Optiskt system innefattande en detektor och en bländare med decentreringsfunktion
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
US7955260B2 (en) 2002-10-18 2011-06-07 Datacquire, Inc. Method for rating severity of psoriasis
NZ539271A (en) 2002-10-30 2008-12-24 Genentech Inc Inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23)
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
AU2003303384A1 (en) 2002-12-23 2004-07-22 Schering Corporation Uses of mammalian cytokine; related reagents
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
CN103040732B (zh) 2003-02-10 2015-04-01 伊兰药品公司 免疫球蛋白制剂及其制备方法
ATE440864T1 (de) 2003-03-10 2009-09-15 Schering Corp Verwendung von il-23-antagonisten; verwandte reagenzien
US20040185506A1 (en) 2003-03-21 2004-09-23 Heavner George A. Epitope mapping using nuclear magnetic resonance
EP1623011B1 (en) 2003-05-09 2013-01-02 Janssen Biotech, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
EP2915820A1 (en) 2004-02-06 2015-09-09 MorphoSys AG Anti-CD38 human antibodies and uses therefor
CN1942201B (zh) 2004-02-17 2012-06-20 先灵公司 调节il-23活性的方法;相关试剂
AU2005241020B2 (en) 2004-05-03 2008-07-10 Merck Sharp & Dohme Corp. Use of IL-17 expression to predict skin inflammation; methods of treatment
WO2005108425A1 (en) 2004-05-10 2005-11-17 Cytos Biotechnology Ag Il-23 p19 antigen array and uses thereof
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
SI1937721T1 (sl) 2005-08-25 2010-11-30 Lilly Co Eli Anti il protitelesa
ME02705B (me) 2005-08-31 2017-10-20 Merck Sharp & Dohme Inženjerisana anti-il-23 antitela
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
US7497060B2 (en) 2007-04-06 2009-03-03 E Z Stairs, Inc. Method for forming a finished skirt/fascia board appearance
EP2205276A4 (en) 2007-09-28 2012-08-15 Janssen Biotech Inc ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
CA2628368C (en) 2008-02-20 2015-04-28 Packers Plus Energy Services Inc. Cut release sub and method
RU2014125071A (ru) * 2011-11-21 2015-12-27 Новартис Аг Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa
US9803010B2 (en) 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
WO2014031718A1 (en) 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
WO2015119841A1 (en) 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Role of il-23 and pd-1 in autoreactive immune response
MY186840A (en) 2014-08-26 2021-08-25 Amgen K A Inc Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
KR20170120616A (ko) 2015-02-04 2017-10-31 베링거 인겔하임 인터내셔날 게엠베하 염증성 질환의 치료 방법
US9353645B1 (en) 2015-02-16 2016-05-31 Borgwarner Inc. Vane ring thermal strain relief cuts
EP3519049B1 (en) * 2016-09-30 2025-12-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
JP7645607B2 (ja) 2016-11-16 2025-03-14 ヤンセン バイオテツク,インコーポレーテツド 抗il23特異的抗体で乾癬を治療する方法
CA3119294A1 (en) 2018-11-15 2020-05-22 Janssen Biotech, Inc. Methods and compositions for prediction of response to a therapy of inflammatory bowel disease
MA55149A (fr) * 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23

Similar Documents

Publication Publication Date Title
US20250340629A1 (en) Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
JP2024088688A (ja) 抗il23特異的抗体で乾癬を治療する安全かつ有効な方法
JP7645607B2 (ja) 抗il23特異的抗体で乾癬を治療する方法
JP2025041599A (ja) 抗il-23特異的抗体で乾癬を治療する安全かつ有効な方法
JP2024510588A (ja) 抗il23特異的抗体による、tnf療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
JP2024038223A (ja) 抗il23特異的抗体で治療した後の持続応答予測因子
JP2024543885A (ja) 抗il23特異的抗体で潰瘍性大腸炎を治療する方法
KR20230084283A (ko) 항-il12/il23 항체로 크론병을 치료하는 방법
KR20220141847A (ko) 항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법
JP2025539830A (ja) 抗il23特異的抗体で潰瘍性大腸炎を治療する方法
JP2024541946A (ja) 抗il23特異的抗体を用いてクローン病を治療する方法
KR20230156387A (ko) 항-il23 특이적 항체에 의해 건선성 관절염을 치료하는 안전하고 효과적인 방법
CN117337302A (zh) 用抗il23特异性抗体治疗对tnf疗法响应不足的银屑病关节炎患者的方法
US20200331996A1 (en) Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
JP2025521118A (ja) Il23抗体を用いて乾癬性関節炎を評価及び治療するための方法
CN118401550A (zh) 用抗il23特异性抗体治疗溃疡性结肠炎的方法
CA3258952A1 (en) Methods of treating ulcerative colitis with anti-il23 specific antibody
EA051014B1 (ru) Способ лечения псориаза антителом к il12/il23 у субъектов детского возраста